In contrast, the combination of VN/66-1 and MS-275 is unlikely to succumb to this potential side effect, because VN/66-1 is a potent RAMBA and does not induce CYP26 enzymes in cancer cells (Patel et al, 2004; Huynh et al, 2006). The gene discussed is CYP26A1; the disease is cancer.